跳至主要内容
临床试验/CTRI/2019/06/019500
CTRI/2019/06/019500尚未招募2 期

A double arm, phase two randomised control study to assess the effect of Resveratrol-Copper in reducing oral mucositis in patients receiving concurrent chemo-radiotherapy for locally advanced oropharyngeal cancers.

Tata Memorial Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Histologically proven oropharyngeal squamous cell carcinoma
  • 2.Male or female patients 18 years and above.
  • 3.Patients who have given written informed consent
  • 4.Patients with performance status of 0,1 or 2 (ECOG scale)
  • 5.Stage III/IV oropharyngeal cancers
  • 6.Patients planned for radical chemoradiotherapy

排除标准

  • a.Medical comorbidities like hypertensive, diabetes mellitus, Hepatitis B and HIV positive, etc.
  • b.Stage I/II oropharyngeal cancers indicated for single modality therapy
  • c.Patient unable to give informed consent.
  • d.Patient unsuitable for radical treatment.

研究者

相似试验